PRGN-3007 is under clinical development by Precigen and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to GlobalData, Phase I drugs for Diffuse Large B-Cell Lymphoma have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PRGN-3007’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

PRGN-3007 overview

PRGN-3007 is under development for the treatment of ROR1 positive hematological, solid tumors, relapsed refractory chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), acute lymphocytic leukemia (ALL), diffuse large B cell lymphoma (DLBCL), b-cell acute lymphocytic leukemia (b-cell acute lymphoblastic leukaemia) and triple negative breast cancer. It is administered through parenteral route. The drug candidate comprises autologous T-cells modified by using a non-viral vector to express a chimeric antigen receptor (CAR) acts by targeting receptor tyrosine kinase-like orphan receptor 1-positive (ROR1) and PD-1 . It also expresses IL15 for the stability of CART cells. The therapeutic candidate is developed based on UltraCAR-T technology.

Precigen overview

Precigen, formerly Intrexon Corp, is a clinical stage biotechnology company that develops synthetic biology solutions. It offers clinical and pre clinical products. The company clinical products include PRGN-3006, PRGN-3005, AG019, PRGN-2009, PRGN-2012 and PRGN-3007. The company’s pre clinical product portfolio comprises of PRGN-3008, PRGN-5001,PRGN-2010, PRGN-2011, PRGN-5002, PRGN-2013, AG017, PRGN-3009 and PRGN-3010. Precigen provides treatment in areas of immuno-oncology, autoimmune disorders, infectious diseases, solid tumors, celiac disease, heart failure, ovarian cancer and type 1 diabetes. It therapeutics platforms include UltraCAR-T, AdenoVerse therapies, ActoBiotics, multifunctional therapeutics, UltraVector, AdenoVerse, AttSite, UltraPorator and RheoSwitch, among others. It erves customers worldwide. Precigen is headquartered in Germantown, Maryland, the US.

For a complete picture of PRGN-3007’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.